The Pharma Data

DECEMBER 14, 2020

A product called DENARASE, which is used in gene and cell therapy, but is also required for production of certain types of vaccines, was the biggest driver of growth in 2020. In the medium term, however, c-LEcta’s management expects demand to develop dynamically, especially from gene and cell therapy. About c-LEcta.

Vaccine 52

Vaccine Production Engineering Therapies 52

Agency IQ

JULY 28, 2023

September 30, 2023 PDUFA Patient-Focused Drug Development (PFDD) Convene a public patient focused drug development meeting with key stakeholders, including patients and patient advocacy organizations, to better understand patient perspectives on gene therapy products, including cell-mediated gene therapy.

FDA 40

FDA Science Biosimilars Regulations 40

The Pharma Data

FEBRUARY 8, 2021

RE47,739 (‘739) by more than four years until March 5, 2027. Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with CDK4/6 inhibitors, including IBRANCE when taken in combination with endocrine therapy. The certificate extends the term of U.S. 2,3 In the U.S.,

Clinical Trials 52

Clinical Trials Treatment Therapies Production 52

The Pharma Data

DECEMBER 30, 2020

This week, Bloomberg reported companies agreed to slash the prices of 119 new therapies that treat a range of illnesses, including pulmonary disease, lupus, diabetes and cancer. billion by 2027. The company’s product candidate is targeting the global metastatic cancer treatment market, projected to be worth $111.2

Immune Response 52

Immune Response Vaccine Clinical Trials Treatment 52

Drug Target Review

MARCH 20, 2025

The landscape of anticoagulation therapy could be on the brink of a major transformation. GI bleeding can lead to patients temporarily or permanently discontinuing their anticoagulation therapy, significantly increasing their stroke risk. “When someone has a GI bleed, they often stop taking their anticoagulant.

Therapies 52

Therapies Clinical Development Trials FDA 52

The Pharma Data

MAY 4, 2021

RE47,739 for Ibrance by more than four years until March 2027. The study evaluated the safety and efficacy of two doses of abrocitinib, 100 mg and 200 mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy. Patent Term Extension certificate extending the term of U.S.

Vaccine 40

Vaccine Production FDA Clinical Trials 40

The Pharma Data

NOVEMBER 25, 2020

The most-favored-nation (MFN) model will be in place between January 1, 2021, and December 31, 2027, allowing time for CMS to evaluate its effect on access to therapeutics, their costs, and quality of care. When this model was issued as an Executive Order on September 13, 2020, the Alliance for Aging Research called it “ a scam for seniors.”

Drugs 52

Drugs International Pharmacy Pharmaceutical Companies 52